Kornimate/medical-research-clean huggingface dataset:
interest of hydrophysiotherapy care in parkinson disease's motor and non-motor symptoms

Conditions: Interest of Hydrophysiotherapy Care in Parkinson Disease's Non-motor Symptoms

Summary: parkinson disease (pd) is a neurodegenerative disorder who begin around 55 years old, characterized by brain's backmatter's dopamine neuron destruction, involved in motor control. diagnosis is made with presence of 3 of 4 disease's cardinal sign: bradykinesia, rigidity, resting tremor, walking troubles. treatments enhance patient's quality of life, but do not allow to stop disease's evolution, who is specific depending on a lot of factors. for some years, pd's non motor symptoms (nms) - in particular pain, anxiety, depression, sleep disorders - have been highlighted and turn out to impair sometimes quality of life even though motor symptoms are controlled. this project's main aim is to evaluate if aquatic environment's care lead to an advantage on pd's nms, symptoms currently underestimated, insufficiently in care and having a harmful influence on quality of life. collaboration of the university hospital (neurology dpt), the physical medicine and rehabilitation regional institute, grand nancy thermal, and france parkinson association, will allow in this way to offer on pd's nms, postural control impairments, and walking troubles an alternative or further non-pharmacological therapy.


Eligibility criteria:
inclusion criteria, patient: * having get a complete information on study's organization and having given written informed consent, * affiliated to a social security system, * suffering from parkinson's disease (stage 2 or 3 of hoehn and yahr), * with motor fluctuation lower than 25% of awaked time, * with dyskinesia lower than 25% of awaked time (according to mds-updrs scale), * with stable pharmacological treatment during the 30 days before study, * already benefiting of a physiotherapy. exclusion criteria, patients: * receiving treatment by apomorphine or duodopa pump, * benefiting of brain stimulation, * taking occasionally benzodiazepine, * with dementia (mds-updrs 1.1 score \> 3), * having had a sprain on a lower limb joint 3 months or less before the beginning of study, * having head trauma consequences, * having vertebrae pain, * with freezing, * having skin trouble leading to a contraindication of aquatic activities, * concerned by l. 1121-5, l. 1121-7 and l 1121-8 articles of french public health code.

Keywords: parkinson's disease non motor signs postural control gait hydrophysiotherapy
functional imagery of sleepwalking

Conditions: Sleepwalking

Summary: sleepwalking (also called somnambulism) is a disorder in which only sws is disrupted. this nrem parasomnia is characterized by inappropriate motor behaviors, usually initiated during arousal from sws, that induce psychological distress and alter quality of life, leading to fatigue, excessive daytime sleepiness, and objectively impaired vigilance in the morning. the pathophysiology of sleepwalking remains poorly understood. sleepwalkers had difficulty maintaining stable, consolidated sleep and experienced more arousals and microarousals, specifically from sws, leading to increased nrem instability, especially during the first sleep cycles. the brain is partially awake, resulting in behavioral manifestations, and partially in nrem sleep, resulting in no conscious awareness of actions. a single photonic emission computed tomography (spect) study of one sleepwalking episode found increased activation in the posterior cingulate cortex and cerebellum, with deactivation in the frontoparietal associative cortices. data from intracerebral eegs during confusional arousals confirmed both local arousal of the motor and cingulate cortices and increased delta activity in the frontoparietal associative cortices. the investigators thus proposed a controlled study of spect imagery in 24 sleepwalkers (12 spect during a sw episode and 12 spect during slow wave sleep and 24 during wakefulness) and 12 controls (during slow wave sleep and wakefulness). sw episodes will be elicited by sleep deprivation condition associated with forced arousal (auditory stimulus). the comparative analyses of spect acquisitions between different states (wakefulness, slow wave sleep and sw) and populations (sleepwalkers versus controls) will provide new insights about the complex pathophysiology of sw episodes.


Eligibility criteria:
patients inclusion criteria: * subject diagnosed with nrem parasomnia according the international classification of sleep disorders * more than one episode per week * more than one hypersynchronous delta wave arousal recorded on polysomnographic assessment * affiliated to social security * age between 18 years-old and 39 years-old exclusion criteria: * patient taking any psychotropic drug during the two weeks before the inclusion * patient with obstructive sleep apnea syndrome, restless legs syndrome, nocturnal epilepsy and unstable psychiatric disease. control group inclusion criteria: * affiliated to social security * age between 18 years-old and 39 years-old exclusion criteria: * subject taking psychotropic drug during the two weeks before the inclusion * subject with following medical history : nrem parasomnia, neurologic or psychiatric disorder, obstructive sleep apnea syndrome, restless legs syndrome, nocturnal epilepsy.
aripiprazole for the augmentation of antidepressant therapy

Conditions: Major Depressive Disorder

Summary: the study aims to evaluate effectiveness and tolerability of aripiprazole augmentation in outpatients with major depressive disorder who have had inadequate response to antidepressants in taiwan clinical practice.


Eligibility criteria:
inclusion criteria: * outpatients, either gender, 20-65 years of age * patients diagnosed with major depressive disorder as defined by diagnostic and statistical manual of mental disorders (dsm-iv), who fulfill both the following criteria: * having at least one and no more than three inadequate responses of antidepressants * ham-d17 score ≥ 14 * willing and able to comply with the study procedure and sign a written informed consent exclusion criteria: * females who are pregnant/lactating or planning to be pregnant * presence of personality disorder cluster b (dramatic, emotional or erratic disorders) or any psychotic symptomatology in the current depressive episode based on investigators judgment * history of organic mental disorder within 1 year prior to the screening visit * acute risk of suicide attempts within 3 months prior to the initiation of study treatment (ham d-17 score item 3 ≥ 3) * electroconvulsive therapy (ect) for current episode * past exposure to aripiprazole treatment or any investigational product (including drug and invasive medical device) within 4 weeks prior to the initiation of study treatment * history of substance / alcohol abuse within 1 year prior to the screening visit * patient with any medical or psychotic feature, including the presence of significant abnormal laboratory values, which is considered not suitable for this study by investigator
impact of aspiresr® for vns therapy on healthcare resource utilisation and clinical outcomes.

Conditions: Epilepsy

Summary: this is a retrospective non-interventional study to describe the hcru and clinical outcomes before and after aspiresr® device implantation in subjects with drug resistant epilepsy at the queen elizabeth hospital, birmingham (qehb).

real-world data on healthcare resource use (hcru) for subjects with treatment-resistant epilepsy and their clinical outcome prior to- and post-vns device implantation in the uk are limited. the current study aims to describe and compare the secondary hcru and clinical outcomes prior to and following aspiresr® device implantation in subjects with drug resistant epilepsy. retrospectively-collected data from hospital medical records (paper-based and/or electronic, as appropriate) will be used to describe subject characteristics, disease control and clinical outcomes. all secondary hcru data will be extracted from the hospital episode statistics (hes) database by harvey walsh ltd (hw, trading under open vie). primary hcru data will be requested from the subjects' general practitioners (gps).

Eligibility criteria:
inclusion criteria: * age ≥18 years at aspiresr® device implantation. * vns device aspiresr® implantation for the first time or battery change from a previous model to aspiresr® at least 24 months prior to the start of retrospective data collection from medical records. * subjects for whom written informed consent has been provided for researcher access to their medical records and extraction of data from hes (if the subject is living and has capacity to consent) or advice from a consultee (if the subject is living but lacks capacity to consent). * subjects with available medical history for at least 24 months prior to aspire sr® implantation. exclusion criteria: * living subjects for whom consent for researcher access to medical records and extraction of data from hes has not been obtained. * deceased subjects.

Keywords: vns drug resistant epilepsy vagus nerve stimulation aspiresr® health care utilization dre
implementation study of the icope program for the detection of frailty in the elderly within the territorial health professional communities (cpts) of brest region

Conditions: Frailty

Summary: frailty is a geriatric syndrome resulting from a decrease in physiological reserve capacities altering the mechanisms of adaptation to stress with, in the absence of diagnosis and management, a short-term risk of falls, hospitalization, loss of autonomy and death. in 2019, the world health organization has taken up this subject with the objective of reducing the number of dependent people in the world by 15 million, i.e. 150,000 in france. for this purpose, recommendations for integrated care for seniors (integrated care for older people = icope) have been published. 6 functions are essential to maintain autonomy: mobility, memory, sight, hearing, mental health and nutrition. the first step of the icope program consists of screening for a decline in one of these functions using a tool made up of questions or tests that can be carried out in 8 to 10 minutes in primary care by trained non-professionals. the second step is a thorough evaluation of the person screened, leading to the creation of a personalized care plan. in the current state of affairs, despite its recommendations, this identification is not carried out in brittany. the objective of this study is to demonstrate the feasibility of implementing the first stage of the icope program by seizing the opportunity of the creation in the brest region of two territorial health professional communities (cpts) : brest santé océane and iroise santé.


Eligibility criteria:
inclusion criteria: * primary care staff belonging to one of the 2 cpts (cpts brest santé océane and cpts iroise santé) and having accepted to participate in the study exclusion criteria: * refusal to participate in the study
prospective study using hybrid pet/mri to evaluate men with suspected recurrence following treatment for prostate cancer

Conditions: Prostate Cancer

Summary: evaluate the impact of hybrid 18f-fluoro-choline (18f-fch) pet/mri imaging on the clinical management of men with suspected recurrent prostate cancer post prostatectomy or radiotherapy. we hypothesize that hybrid imaging incorporating 18f-fch pet/mri imaging will be feasible and will lead to changes in management decisions among men being re-staged for suspected prostate cancer recurrence post-surgery or radiation who are potentially eligible for local salvage therapy.

the study will be a non-randomized, prospective study of men with suspected local recurrence of prostate cancer post-prostatectomy or radiation with negative bone and ct scans. hybrid pet/mri using 18f-fch will be obtained and a consensus staging report generated for the attending clinician. clinical management questionnaires completed by the study investigator will be obtained pre and post imaging in order to gauge the impact of the hybrid imaging on clinical decision making.

Eligibility criteria:
inclusion criteria: * prostate cancer with rising prostate specific antigen (psa) post prostatectomy or radiotherapy * suspected recurrence based on psa rise measured on 3 occasions at least 3 months apart and an absolute psa \> 0.2 ng/ml * bone scan and ct scan of the abdomen and pelvis negative for metastatic disease exclusion criteria: * evidence of metastatic disease * contradiction to 18f-fch pet scan * contraindication to mri

Keywords: prostate cancer pet mri hybrid recurrence fluorocholine
effect of vr vs conservative treatment in sensorimotor function of upper extremity in chronic stroke patients

Conditions: Chronic Stroke

Summary: virtual reality (vr) therapy has shown promising results in improving sensorimotor function of the upper extremity in chronic stroke patients compared to conservative treatments. vr offers immersive, interactive environments that can enhance motivation and engagement in rehabilitation exercises. studies have indicated that vr can lead to significant improvements in motor function, coordination, and strength of the affected upper limb.

these advancements are often attributed to the ability of vr to provide real-time feedback, varied and repetitive tasks, and the stimulation of neuroplasticity. in contrast, conservative treatments, such as traditional physical and occupational therapy, though beneficial, may not offer the same level of stimulation and engagement. overall, vr therapy can be a valuable adjunct to traditional rehabilitation, potentially accelerating recovery and improving functional outcomes for chronic stroke patients by providing a more dynamic and engaging approach to therapy.

Eligibility criteria:
inclusion criteria: * patients with a confirmed diagnosis of chronic stroke (at least 6 months post-stroke). * adults aged 18 years and older. * demonstrable sensorimotor impairment of the upper extremity due to stroke, as assessed by clinical evaluation. * sufficient cognitive ability to follow instructions and participate in vr therapy, as determined by a mini-mental state examination (mmse) score of 24 or higher. * medically stable and able to participate in physical rehabilitation sessions, as cleared by a healthcare professional. exclusion criteria: * severe communication difficulties that would impede the ability to follow instructions during therapy. * severe spasticity in the affected upper limb (modified ashworth scale score of 4 or higher)
multicenter, safety study of maraviroc

Conditions: Acquired Immunodeficiency Syndrome; HIV Infection

Summary: to collect safety and tolerability data in a more diverse patient population of patients with hiv/aids, who have limited therapeutic options.


Eligibility criteria:
inclusion criteria: * subjects with limited or no approved treatment options available to them due to resistance or intolerance; * subjects must be failing to achieve adequate virologic suppression on their current regimen and have hiv-1 rna ≥ 1000 copies/ml, at screening. * have only r5 hiv-1 at screening as verified by the monogram biosciences trofile assay. exclusion criteria: * failed prior treatment with any ccr5 antagonist, in any ongoing ccr5 trials or having previously discontinued maraviroc in trials * potentially life threatening (grade 4) laboratory abnormality or medical condition (according to the division of aids table for grading severity of adult adverse experiences) still under investigation unless a diagnosis has been established and felt not to affect risk/benefit assessment or eventual interpretation of safety results, based on discussion between the investigator and pfizer.

Keywords: multicenter open label non-comparative safety study of maraviroc treatment experienced
decision variability between different heart teams for complex coronary artery diseases

Conditions: Coronary Artery Disease

Summary: the purposes of this study are 1) to explore the variability of decisions between different heart teams in complex coronary artery disease; 2) to evaluate the reasons of the discrepancy in decision making.

heart team has been recommended by guideline for optimizing the decision making for patients with complex coronary artery diseases (cad). however, prior studies have demonstrated that heart team decision might have poor reproducibility, and the variability of heart team decision remains unknown. thus, the investigators designed a single-center, retrospective, cross-sectional study to explore the decision variability of heart team in cad patients. the investigators will retrospectively recruit patients with angiographically confirmed 3-vessel or left main disease from a coronary angiography database at fuwai hospital. patients' baseline information will be collected. and different heart teams will be established and made decisions for the enrolled patients. first, the investigators will assess the decision variability between different heart teams. secondary, the investigators will evaluate the reason of discrepancy by qualitative and quantitative analysis.

Eligibility criteria:
inclusion criteria: * patients with angiographically confirmed 3-vessel disease or left main disease exclusion criteria: * prior percutaneous coronary intervention (pci) or coronary artery bypass graft (cabg) * myocardial infarction with acute phase judged by electrocardiograph or biomarkers * combined with severe valvular disease, great vessel disease or huge ventricular aneurysm which need surgery * combined with atrial fibrillation or severe arrhythmia

Keywords: heart team decision making complex coronary artery disease
azd1152 in patients with advanced solid malignancies-study 1

Conditions: Solid Tumors

Summary: the primary purpose of this protocol is to investigate the safety and tolerability of azd1152 when given as a continuous 2-hour infusion every week and every 2 weeks in patients with advanced solid malignancies.


Eligibility criteria:
inclusion criteria: * histological or cytological confirmation of a solid, malignant tumour * at least measurable or non measurable site of disease as defined by modified recist criteria. exclusion criteria: * participation in an investigational drug study within 30 days prior to entry or who have not recovered from the effects of an investigational study drug * treatment with radiotherapy/chemotherapy with 4 weeks of first dose * recent major surgery within 4 weeks prior to entry to the study

Keywords: advanced solid tumors
chart review of repatha® in subjects with hyperlipidaemia

Conditions: Hypercholesterolaemia

Summary: review of clinical characteristics of patients who are prescribed repatha® and how their treatment is managed.


Eligibility criteria:
inclusion criteria: adults (\>18 years) provided informed consent initiated on repatha® at physician's discretion, after 1st august 2015 received at least one dose of repatha® exclusion criteria: enrolled in an interventional study of pcsk9 inhibitor within 12 weeks prior to initiation of repatha® received commercially available pcsk9 inhibitor within 12 weeks prior to initiation of repatha®

Keywords: hypercholesterolaemia lipid-lowering therapies
follow up study for treatment of parkinson's disease with subthalamic deep brain stimulation

Conditions: Parkinson Disease

Summary: this study aims to evaluate the long term effect of deep brain stimulation in the the subthalamic nucleus (stn) in patients with parkinson's disease.


Eligibility criteria:
inclusion criteria: * idiopathic parkinson's disease * disease duration longer than 15 years * had stn deep brain stimulation implant more than 10 years * available and willing to be followed-up according to study protocol exclusion criteria: * patients with serious diseases such as tumor, sever liver or kidney dysfunction were not selected in the clinical trials * epilepsy * pregnant female * history of severe neuropsychiatric disease * patients are taking part in other clinical trials in recent several months
sexual health of spinal cord injured females

Conditions: Spinal Cord Injuries

Summary: the purpose of this study is to assess the impact on sexuality in women with a spinal cord injury, twelve months after their first return to home, of a program including structured information and education on sexuality, delivered 6 months after their first return to home.

multicentre, prospective study, aiming to assess the effect on sexuality of an information and education program in women with spinal cord injury. included patients will be women hospitalized for initial rehabilitation, and will be included two weeks before their first return to home. socio-demographic data, diagnosis and etiology, secondary conditions, treatment, comorbidities and expectations towards rehabilitation care will be assessed at inclusion. at m3 patients will be randomized in either the intervention arm or the control arm. patients enrolled in the intervention arm will benefit from a standardised information and education consultation on physiology of sexual response 6 months after their return home. patients enrolled in the control arm will undergo the same follow-up but will only have the usual unstructured and unformalized information provided by the clinical team. at m3, m6, m12 secondary conditions , sexual function index (fsfi), social integration (lhs), treatment and expectations towards rehabilitation care will be assessed

Eligibility criteria:
inclusion criteria: * spinal cord injury including cauda equina injury of traumatic etiology or not * hospitalization for initial post-injury rehabilitation in a study center * first return at home scheduled within the 14 days following inclusion date * understanding of the french language allowing to answer questionnaires * affiliation to health insurance * written informed consent exclusion criteria: * full recovery of sensory-motor functions (aise) * associated brain injury * psychiatric disease previously diagnosed, excepted treated and remitting mood disorders * patients with tutorship / guardianship * spinal cord injury of malignant origin * spinal cord injury associated with multiple sclerosis * anticipated loss-to-follow-up (patient moving outside of the usual hospital catchment area)

Keywords: spinal cord injuries sexual function sexual response sexuality women
intravenous haloperidol versus ondansetron for treatment of established post-operative nausea and vomiting

Conditions: Postoperative Nausea and Vomiting

Summary: this study aims to prove that at a dose of 1 mg haloperidol possesses a high success rate in controlling established postoperative nausea and vomiting (ponv) in the first 24 hours following administration similar to the standard of care ondansetron 4 mg.

patients undergoing surgery under general anesthesia may experience several complications in their postoperative period. nausea and vomiting are some of the more common of these complications. several medications can be used for prevention of these specific complications, but treatment remains more cost-efficient. haloperidol is anti-psychotic which, at low doses, can prevent the occurrence of nausea and vomiting. its usefulness for prophylaxis has been demonstrated in several studies. however, its use for treating established postoperative nausea and vomiting (ponv) has not been properly studied. in a prospective randomized clinical trial involving adult patients undergoing elective surgery under general anesthesia, investigators will enroll 120 patients, and compare the effect of a dose of 1 mg haloperidol versus ondansetron 4 mg and document the varying degrees of success in treating nausea and vomiting as well as possible side effects. investigators expect to observe that haloperidol is as effective as treatment with ondansetron.

Eligibility criteria:
inclusion criteria: * patients aged 18-80 * asa class i, ii, and iii * undergoing elective surgery under general anesthesia exclusion criteria: * patients with history of arrhythmias, qtc prolongation or allergies to the study drugs will be excluded from the study.